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ABSTRACT
Decisions to adopt medical devices at the hospital level have consequences for health technology assessment (HTA) on sys-
tem level and are therefore important to decision makers. Our aim was to investigate the characteristics of organizations and
individuals that are more inclined to adopt and utilize cardiovascular devices based on a comprehensive analysis of environ-
mental, organizational, individual, and technological factors and to identify corresponding implications for HTA. Seven
random intercept hurdle models were estimated using the data obtained from 1249 surveys completed by members of the
European Society of Cardiology. The major findings were that better manufacturer support increased the adoption probabil-
ity of ‘new’ devices (i.e. in terms of CE mark approval dates), and that budget pressure increased the adoption probability of
‘old’ devices. Based on our findings, we suggest investigating the role of manufacturer support in more detail to identify
diffusion patterns relevant to HTA on system level, to verify whether it functions as a substitute for medical evidence of
new devices, and to receive new insights about its relationship with clinical effectiveness and cost-effectiveness. © 2017
The Authors. Health Economics published by John Wiley & Sons, Ltd.
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1. INTRODUCTION
The adoption of innovations is a major topic of interest for decision makers in the area of health technology
assessment (HTA) (Bryan et al., 2014). One of the basic concerns of these decision makers is to balance cost
containment pressures and ensure the access to innovative and effective technologies (Rye and Kimberly, 2007;
Feder and Umali, 1993; Gopalakrishnan and Damanpour, 1997; Robert et al., 2010). This trade-off implies a
system perspective; however, in many European countries, the decisions to adopt medical technologies take
place at the hospital level (Sorenson and Kanavos, 2011). In the hospitals, technology adoption is a process in-
volving various stakeholders (Stefanidis et al., 2014). These include hospital managers and (senior) physicians,
where the latter play a major role in priority setting and technology adoption (Robert et al., 2010; Boriani et al.,
2013; Gurtner, 2014; Barasa et al., 2015). Understanding the factors that lead to the adoption of medical de-
vices is especially important for health care decision makers in Europe because the regulatory barriers to market
access are considerably lower for medical devices than for pharmaceuticals. European marketing authorization
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for pharmaceuticals requires a rigorous assessment of quality, safety, and efficacy, while marketing authoriza-
tion for medical devices requires only a CE mark and an evaluation of clinical data for high-risk devices
(Greenberg et al., 2005; Robert et al., 2010). As the market access barriers at the EU level are rather low,
the emphasis is on understanding the mechanisms behind adoption decisions at the hospital level. In the past,
one of the main questions addressed in the literature was which factors actually drive the adoption process
(European Commission, 2015; Vinck et al., 2007). These results were multifaceted (Vinck et al., 2007), leading
to the view that the answer to that question is not straightforward. Theoretical models suggest that the adoption
of innovations is driven by factors on various levels (Wisdom et al., 2014), and papers summarizing the avail-
able empirical evidence confirm this assertion (Ghodeswar and Vaidyanathan, 2007; Wisdom et al., 2014;
Straub, 2009; Greenhalgh et al., 2004; Rye and Kimberly, 2007). Four different levels were identified to be
especially important across studies: the environmental level, the organizational level, the individual level, and
the technological level. The majority of empirical studies did not account for all of these levels, examining only
one or two (Wisdom et al., 2014). This led to a call for broader analyses and multilevel models considering the
more complex nature of the adoption process (Fleuren et al., 2004; Robert et al., 2010; Rye and Kimberly,
2007). In addition to the need to allow for the complexity of adoption, there are research gaps concerning the
influence of certain variables. For example, Rye and Kimberly (2007) suggested that more research is needed
to clarify the role of marketing by manufacturers, the interconnectedness of adopting organizations (i.e. of
people within the organizations), and the roles of physiciansˈ values, norms, and interests.
We believe that an increased knowledge about how adoption decisions are made at the hospital level has
important implications for the adoption and diffusion of medical devices for HTA on system level as well as
for health economic evaluations of such devices after their initial introduction to the market (Williams and
Bryan, 2007).
Therefore, the aim of this study is to conduct an extensive analysis incorporating environmental, organiza-
tional, individual, and technological factors to determine whether they influence the adoption and utilization of
medical devices. Moreover, our aim is to investigate the characteristics of organizations and individuals that are
more inclined to adopt medical devices; to study the role of perceived medical evidence and financial criteria at
the time of the adoption decision; and to examine the role of manufacturer support and physician motivation—
variables which are assumed to be important but were hardly addressed in research studies to date.
2. METHODS
2. 1. Survey development and data collection
Seven implantable cardiovascular devices/procedures were selected for the analysis: Implantable Cardioverter
Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT), Drug-eluting Stent (DES), Transcatheter Aor-
tic Valve Implantation (TAVI), Renal Denervation (RD), Left Atrial Appendage Closure Device (LAA), and
MitraClip (MC). These devices were chosen after consulting medical experts based on their relevance and dif-
ferent profiles of medical evidence and stages in the diffusion process. CE mark approval dates were used to
proxy for the latter (see Table II). We referred to all devices with CE mark approval dates before 2007 as
‘old’ devices. All devices with CE mark approval dates since 2007 were termed ‘new’ devices. According to
our experts, medical evidence for RD, MC, and LAA was weak or unclear. In contrast, they described the med-
ical evidence supporting the other devices as strong or good.
The data were collected using an online survey that was incorporated into the regular ESC newsletter. The
newsletter was sent to 85 568 members and affiliates of the European Society of Cardiology (ESC) with se-
lected fields of interest (e.g. Acute Coronary Syndromes, Heart Failure, Interventional Cardiology). The factors
included in the online survey were selected based on a review of the available literature. Our pre-selection was
obtained from an extremely large number of potentially important drivers of the adoption and utilization of
medical devices that have been identified in the literature. This pre-selection of factors was validated by a
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subsequent pilot study with 17 cardiologists from four European countries (Germany, Italy, England, and
Slovenia). The pilot study was conducted via face-to-face or telephone interviews. The interviewees were asked
to go through the online survey and were questioned using a semi-structured field manual. The field manual
included questions on survey content, item selection/relevance, survey structure, and item wording. The inter-
views were audio recorded, and the answers were entered into standardized collection forms. Both the re-
sponses and feedback provided during the interviews were evaluated, and the questionnaire was revised
accordingly.
The final online survey included between 6 and 54 items, depending on the path that the respondent
followed through the survey (see Appendix). Respondents who indicated that they use at least one of the de-
vices on our list were defined as adopters. Respondents who indicated that they do not use all of the devices
on our list were asked whether the requirements to utilize the remaining devices are fulfilled in their hospitals.
Respondents who agreed with this question were defined as non-adopters, and respondents who did not agree
with this question were defined as ‘excess zeros’. As a result, we compared adopters and non-adopters that had
the possibility to adopt the devices on our list in our study.
The independent variables consisted of individual respondent characteristics (e.g. sex, age group, specialty,
experience in cardiology or similar department), device-related factors (e.g. quality and quantity of medical ev-
idence, trialability, costs), a validated scale with 20 items to measure four dimensions of motivation (hedonic,
functional, social, cognitive) (Wisdom et al., 2014), organizational factors (e.g. hospital size), and environmen-
tal factors (e.g. regional location of the hospital). The device-related factors, motivation factors, and some of the
organizational factors were measured using a 5-point Likert scale with an additional ‘donˈt know’ option. That
is, we measured the physiciansˈ perceptions of these factors. Other factors were measured using yes/no answer
options, choice lists, or open fields. We incorporated the number of devices utilized as a dependent variable,
which made it possible to separately analyse the factors that influence adoption and utilization decisions.
The online survey was distributed as a part of the ESC newsletter to ESC members and affiliates on 26/09/
2014. The initial invitation to participate in the survey was followed by three reminders (sent on 23/10/2014,
19/11/2014, 09/01/2015), and the data collection phase was completed on 19/01/2015.
Additional environmental-level (i.e. country level) data were collected. The data for GDP and out-of-pocket
payments in health systems were obtained from publicly available databases: World Bank Open Data, OECD
Health Statistics, and WHO World Health Statistics. All data were obtained for 2012, as this was the latest
available. Where necessary, currencies were transformed into US dollars using currency exchange rates dating
to 01/07/2012.
2. 2. Data refinement and missing values
This analysis focused on hospital physicians and therefore excluded non-physicians, students, retired physi-
cians, and physicians without hospital affiliations. Unrealistic entries (e.g. 100 years of experience) and re-
sponses from individuals who did not report a country of origin were excluded as well.
We conducted exploratory and confirmatory factor analyses to test the validity of the motivation scale. The
results were satisfying and are available from the authors upon request.
Respondents were given the option to select ‘donˈt know’ answers in addition to the 5-point Likert scale op-
tions. These answers were treated as missing values (missing at random (MAR)). To avoid loss of information
because of case deletion, multiple imputation was conducted (Simpson, 2002). Markov Chain Monte Carlo
simulation was used for the multiple imputation procedure because no monotone missing patterns were iden-
tified via visual inspection using PROC MI (SAS Institute, Cary, NC). The literature suggests at least five im-
putations to produce results that appropriately reflect the uncertainty related to the imputation of missing values
(Lansisalmi et al., 2006). Because the optimal number of imputations is still unclear, we conducted 10. This
number balanced more appropriate estimates with acceptable computing times. All analyses were conducted
using PROC MI and PROC MIANALYZE in SAS 9.4 (SAS Institute, Cary, NC, USA), and Stata 13 SE
(StataCorp LP, College Station, TX, USA).
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2. 3. Data analysis
As suggested by the literature (Vandecasteele and Geuens, 2010; Rubin, 1996), we assume that adoption
and utilization decisions reflect two separate, consecutive processes. The adoption decision is made first
on basis of certain factors, and the number of devices utilized is subsequently decided. Therefore, we
employed count data hurdle models to analyse each of the seven cardiovascular devices. Count data hur-
dle models combine a binary model with a zero-truncated model (Johnson and Young, 2011; Rye and
Kimberly, 2007). The flexibility of these two-part models (i) addressed more zero counts than are pre-
dicted by a standard Poisson count data model and (ii) differentiated between the adoption and the imple-
mentation decisions (Greer, 1981).
In the first part of the model, we used a logit regression to estimate the likelihood of device adoption. In the
second part of the model, we used a truncated negative binomial model (type II) to estimate the number of de-
vices utilized. The Akaike Information Criterion (AIC) and the Bayesian Information Criterion (BIC) indicated
that the negative binomial model outperformed the Poisson model (Mullahy, 1986; Winkelmann and Zimmer-
mann, 1995; dˈUva, 2006). Furthermore, the negative binomial model can handle overdispersion (i.e. the var-
iance exceeds the mean), which we observed in our data (Saffari et al., 2012). The hurdle models included 37
variables in the logit regression and 14 variables in the truncated negative binomial model. The data set was
divided into seven sub-sets, one for each cardiovascular device, which formed the basis of the analyses. This
was done because the cardiovascular devices in our data set did not represent substitutes or complements;
hence, we assumed no interdependencies between the devices.
We accounted for the hierarchical structure of the data in all models, allowing for correlation between ob-
servations within the same country using random intercepts. The random effects were assumed to be normally
distributed and to be uncorrelated with other explanatory variables. The choice of random effects over fixed
effects was based on the structure of our data. Our sub-sets included a large number of singletons (i.e. countries
with a single observation). The percentage of singletons in the data set ranged between 18% (for ICD) and 38%
(for MC). Countries with five or fewer observations accounted for more than one-half of the observations
(between 52% for ICD and 59% for MC). In a fixed effects model, such a data structure would cause problems
because of small within-country variation. Random effects models are preferable in that case, even when the
assumption of zero correlation between the independent variables and the random effects is violated (Burnham
and Anderson, 2004). Regarding the accuracy of the parameter estimates and their corresponding standard
errors, the proportion of singletons is only problematic when the number of level-two groups is too small (Kuha,
2004). For example, a low number of level-two groups (<30) and a high proportion of singletons (>30%) can
cause imprecise confidence intervals for level-two predictors. However, it will not impact the precision of the
confidence intervals of the first-level predictors (Min and Agresti, 2005). Although we had a relatively high
proportion of singletons in some of our sub-sets, the number of groups on the second level never dropped be-
low 60. Therefore, the estimates and standard errors obtained by these random effects models should not be
biased. Empirical sandwich estimators of the covariance matrix were used to obtain robust standard errors.
We used Gauss adaptive quadrature to estimate the models. All estimations were conducted using SAS PROC
NLMIXED (SAS Institute, Cary, NC, USA).
The adoption and utilization of these cardiovascular devices were analysed using the following hurdle
model. Let yij be the number of devices adopted by the i
th, i = 1 ,…, ni individual in the j
th, j = 1,…,mj country:
Pr Y ij ¼ yij
 
¼ 1 wij
  wij; yij ¼ 0g
1 1þ αμij
 α1 ; yij; > 0
8>><
>>:
where μij=exp (xijβ), α(≥0) is a dispersion parameter, and xij is a vector of explanatory variables. Suppose that
0<wij< 1,wij is modeled using a logit link function
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is the likelihood function of the negative binomial function. The hurdle models were specified as follows.
Logit part:
log wij
  ¼ log wij
1 wij
 
¼ α0 þ devijαþ indijyþ orgijδþ envijζ þ countryjηþ b1j
where devij is a vector of covariates at the technology level, indij is a vector of covariates at the individual level,
orgij is a vector of covariates at the organizational level, and envij and countryj are vectors of covariates at the
environmental level. Here, α, γ, δ, ζ, and η are the corresponding vectors of parameter estimates, and b1j rep-
resents a random variable that is independently and normally distributed, b1j ~ N(0,σ2).
Truncated negative binomial part:
log μij
 
¼ β0 þ devijβ þ hospijk þ envijξ þ countryjτ þ b2j
where devij is a vector of covariates at the device level, hospij is a vector of covariates at the organizational
level, and envij and countryj are vectors of covariates at the environmental level. Here, β, κ, ξ, and τ are corre-
sponding vectors of parameter estimates, and b2j represents a random variable that is independently and nor-
mally distributed, b2j ~ N(0,σ2).
Additional sensitivity and subgroup analyses were conducted. In the first sensitivity analysis, we estimated
the models using country fixed effects instead of random effects. To estimate the models (i.e. to ensure enough
within-country variance), the singletons and countries with fewer than 20 observations were eliminated. After
reducing the data sets, very few non-adopters were left for ICD, CRT, and DES, which consequently did not al-
low country fixed effects to be estimated in the logit parts of these models. In these cases, the model distribution
was changed to a negative binomial including fixed effects. Comparing the results of the fixed effects models to
our benchmark models was problematic because different data sets were used to estimate the models (the full
data sets vs. the reduced data sets). Therefore, we also estimated random effects models using the reduced data.
In the second sensitivity analysis, we estimated our models based on a sample restricted to complete cases to test
the influence of the multiple imputation procedure. Finally, we conducted an additional subgroup analysis in
which the random effects models were estimating including only the observations from the EU28 countries.
3. RESULTS
3. 1. Descriptive results
Across all mailings, 56 255 people clicked on the ESC newsletter. A total of 4922 of these clicked on the link to
our survey, and 1773 people completed our questionnaire. The response rate based on the number of people
who clicked on the ESC newsletter was 3%. The response rate based on the number of people who clicked
on the link to our survey was 36%. After data cleansing, our final data set consisted of 1249 observations. De-
scriptive statistics for all of the included variables are presented in Tables I and II. Overall, the observations
were clustered into 89 different countries, including all of the EU28 countries. Our sample included 81 coun-
tries (91%) which are included in the ESC members and affiliates lists. As expected, approximately 61% of
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physicians in the sample were chiefs of cardiology departments and senior physicians. The size of each sub-set
was determined by the sum of adopters and non-adopters per device, which ranged from 459 (MC) to 1141
(ICD).
3. 2. Results of the hurdle models
Comparing the significant results (p-value <0.05) in the logit parts of the hurdle models across devices, three
patterns were identified: significant results for the ‘new’ devices, that is, TAVI, RD, MC, and LAA; significant
results for the ‘old’ devices, ICD, CRT, DES; and significant results across these two groups of devices. In the
Table I. Descriptive statistics for the included environmental-, organizational-, and individual-level covariates
Covariates Category/(measurement) Mean (SD)/percentage
Environmental level
GDP (US-$/10 Billion) 143.30 (196.29)
Out-of-pocket payments in health system (US-$/10 Billion) 2.41 (3.62)




Exp. ch. in human resources (Likert 1–5) 3.45 (0.84)
Exp. ch. in work flows (Likert 1–5) 3.47 (0.79)
Exp. ch. in the planning of activities (Likert 1–5) 3.37 (0.79)
Exp. ch. in organizational structure (Likert 1–5) 3.42 (0.85)
Relative department size (Likert 1–5) 3.46 (1.04)
Budget pressure (Likert 1–5) 3.80 (0.94)
Competitive pressure (Likert 1–5) 2.95 (1.01)






Experience (years) 15.39 (9.64)
Number of visits of scientific conferences (per year) 6.27 (7.00)
Number of visits of manufacturer exhibitions (per year) 2.60 (3.37)
Number of salesman visits (per year) 7.13 (10.62)
Hedonic motivation (score 5–25) 19.27 (3.69)
Functional motivation (score 5–25) 20.83 (2.61)
Social motivation (score 5–25) 14.81 (4.86)
Cognitive motivation (score 5–25) 18.15 (3.56)
Sex Male 75.98%





Medical specialty Int. car. 23.62%
Elec. 29.14%








Additional economic qualification With qualification 9.85%
Likert items: higher values indicate higher agreement (1: strongly disagree; 5: strongly agree). Motivation dimensions: higher values indi-
cate higher agreement (scores are sums from five Likert items). All values are based on complete cases.
SD: standard deviation; Exp. ch.: expected change; Int. car.: interventional cardiologist; Elec.: electrophysiologist.
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group of ‘new’ devices, manufacturer support was associated with an increase of the log odds of adoption. Fur-
thermore, physicians had higher log odds of adoption compared to chief physicians for TAVI, MC, and LAA
(and for ICD). In the group of ‘old’ devices, higher budget pressure in the context of adoption increased the log
odds of adopting ICD and CRT (the opposite result was found for LAA). Across devices, larger hospitals (ICD,
CRT, DES, TAVI, MC) and urban hospital locations (ICD, CRT, DES, RD, LAA) were associated with higher
log odds of adoption. Electrophysiologists had higher log odds of adoption compared to interventional cardi-
ologists for ICD, CRT and TAVI. Better medical evidence (as perceived by the physicians) was associated with
an increase in the log odds of adoption for ICD and TAVI. The parameter estimate for hospital-level costs was
significant for TAVI. There were very few findings for the motivation variables and the variables capturing the
expected impact of the adoption decision. Many of the other estimates were significant for only one or two de-
vices without producing coherent patterns across devices or were not significantly different from zero.
Further results were identified in the truncated negative binomial parts of the hurdle models. In the
group of ‘old’ devices, greater hospital size (size3: ICD, size4: ICD and DES, size5: ICD) and greater
relative size of the cardiology department (department size) (ICD, CRT, DES, and LAA) were signifi-
cantly associated with a higher number of devices utilized. Across devices, urban hospital location
(ICD, DES, TAVI, MC), higher GDP (ICD, CRT, TAVI), and lower out-of-pocket payments (CRT,
TAVI) were also associated with a higher number of devices utilized. Regarding the covariates at the de-
vice level, better perceived medical evidence increased the number of CRTs and LAAs utilized. In addi-
tion, the absence of manufacturer support increased the usage of the same devices and MC. The results
for cost-effectiveness were mixed, as better perceived cost-effectiveness increased the number of DES and
decreased the number of LAAs used. Tables III and IV display all results of the random intercept hurdle
models.
3. 3. Sensitivity and subgroup analyses
First, we re-estimated the models allowing for fixed effects. Thus, a reduced data set was created to in-
crease within-country variation. All data sets were restricted to include only countries with at least 20 ob-
servations. This reduced each data set to approximately 50% of the observations. In addition, the number
of hospital size categories was reduced from five to four, as there were very few observations left in size
category five, and the GDP and out-of-pocket payments variables were excluded. All logit models were
estimated using cluster-robust standard errors. It was not possible to estimate logit models with country
fixed effects for DES, CRT, or ICD because the number of non-adopters was too small, that is, in some
countries, there were no non-adopters. For these devices, truncated negative binomial models with fixed
effects were estimated. Because the comparison of the fixed effects and the random effects models was
problematic because of the large differences in the sample size, the random effects models were re-
estimated based on the reduced data sets. All of the findings of the fixed effects models (except the sig-
nificant results for hospital size3 (ICD) and size4 (ICD, RD) in the truncated negative binomial models)
were confirmed by the random effects models. However, as expected, the standard errors of the random
effects models were smaller than those of the fixed effects models.
Second, we estimated the models based on complete cases to test the influence of the multiple impu-
tation procedure on our results. Case deletion reduced the number of observations used for the analysis by
a minimum of 8% (truncated negative binomial part of ICD) up to a maximum of 41% (logit part of
MC). In general, the number of observations lost was higher for the new than for the old devices. Over-
all, it cannot be concluded that the multiple imputation procedure had a clear tendency to increase or de-
crease p-values (i.e. both occurred). As highlighted in Tables III and IV, most of our main findings
remained unchanged (i.e. the effects were in the same directions and p-values <0.05). Substantial changes
were observed in the logit parts of the models for the variables medical evidence, costs, cognitive moti-
vation, senior physician, competitive pressure, expected change in work flows and in the planning of ac-
tivities, suburban region, hospital size5, department size, and urban region. For these variables, our
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previous findings were (partly) not confirmed (i.e. p-value >0.05), or the results occurred only in the sen-
sitivity analysis (i.e. p-value <0.05). In the truncated negative binomial parts of the models, substantial
changes were observed for the variable manufacturer support and hospital size3. The other results
remained mostly unchanged.
Third, the major findings of the first subgroup analysis (only EU28 observations) were identical to the
base case random effects models for greater hospital size, electrophysiologists and budget pressure (i.e.
the effects were in same direction and had p-values <0.05). Fewer results were found for the role of
manufacturer support (which was significant only for TAVI and LAA), urban hospital location (only
Table III. Results of the random intercept hurdle models (logit part)
Devices
Covariates ICD CRT DES
Technology level
Intercept1 3.35 (2.18) 2.04 (1.58) 3.63 (5.15)
Medical evidence 0.19 (0.09)** 0.2 (0.11). 0.14 (0.24)
Man. support 0.15 (0.16) 0 (0.19) 0.36 (0.27)
Costs 0.04 (0.15) 0.1 (0.16) 0.4 (0.32)
Profitability 0.24 (0.18) 0.16 (0.15) 0.04 (0.22)
Cost-effectiveness 0.03 (0.21) 0.14 (0.2) 0 (0.29)
Individual level
Hedonic mot. 0.04 (0.06) 0.08 (0.05) .†0.14 (0.06)**
Functional mot. 0.12 (0.07). 0.1 (0.07) 0.15 (0.12)
Social mot. 0.01 (0.04) 0.01 (0.04) 0.03 (0.07)
Cognitive mot. 0.08 (0.05) 0.04 (0.04) 0.06 (0.07)
Experience 0 (0.01) 0.02 (0.02) 0.01 (0.03)
Scientific conf. 0.05 (0.04) 0.03 (0.02) 0.02 (0.05)
Sales visits 0.01 (0.02) 0.01 (0.02) 0.04 (0.03)
Senior phy. 0.42 (0.33) 0.67 (0.29)** 0.38 (0.61)
Attending phy. 0.87 (0.53). 0.78 (0.45) .0.55 (0.66)
Phy. †1.18 (0.58)** 0.62 (0.6) 0.59 (1.04)
Elec. †1.45 (0.59)** †1.65 (0.49)*** 1.22 (0.76)
Heart surgeon 0.88 (1.27) 0.4 (1.04) 0.92 (0.88)
Elec. and Int. car. 1.68 (0.99). 0.53 (0.55) 1.54 (1.29)
General cardio. 0.56 (0.38) 0.11 (0.33) 1.31 (0.71).
Other physician †1.05 (0.51)** 0.13 (0.55) 1.04 (1.06)
Sex (male) 0.03 (0.35) 0.16 (0.25) 0.33 (0.47)
Additional qual. 0.35 (0.39) 0.49 (0.29) .0.55 (0.93)
Organizational level
Hosp. size2 0.28 (0.36) 0.18 (0.32) 0.75 (0.46)
Hosp. size3 0.13 (0.39) 0.02 (0.39) 0.91 (0.61)
Hosp. size4 1.69 (0.62)** 1.22 (0.59)** †2.07 (0.98)**
Hosp. size5 †1.74 (0.67)** 0.64 (1.03) 1.56 (1.88)
Department size 0.05 (0.15) 0.11 (0.11) 0.41 (0.21).
Budget pres. †0.45 (0.16)** †0.36 (0.13)** 0.12 (0.24)
Competitive pres. 0.24 (0.21) 0.08 (0.14) 0.39 (0.25)
Exp. ch. hum. res. 0.14 (0.18) 0.23 (0.21) 0.06 (0.35)
Exp. ch. work flows 0.1 (0.23) 0.03 (0.26) 0.02 (0.34)
Exp. ch. plan. 0.01 (0.23) 0.11 (0.24) 0.12 (0.41)
Exp. ch. org. 0.01 (0.25) 0.1 (0.21) †0.82 (0.39)**
Environmental level
Suburban region 0.45 (0.69) 0.64 (0.46) 0.59 (0.83)
Urban region †0.84 (0.4)** †1.08 (0.39)** 1.66 (0.69)**
GDP 0 (0) 0 (0) 0 (0)
Out-of-pocket pay. †0.52 (0.26)** 0.13 (0.13) 0.38 (0.25)
ICC 0.25 0.14 0.01
(Continues)
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significant for CRT), costs (only significant for RD), and medical evidence (significant for TAVI and
CRT but no longer for ICD). The former results for the physician and suburban location variables disap-
peared. In the truncated negative binomial models, greater hospital size, greater relative department size,
Table III. (Continued)
Devices
Covariates TAVI RD MC LAA
Technology level
Intercept1 †5.36 (2.03)** 3.27 (1.44)** †6.44 (1.69)*** 3.35 (1.26)**
Medical evidence 0.29 (0.11)** 0.12 (0.07) 0.14 (0.09) 0.05 (0.08)
Man. support †0.55 (0.2)** †0.37 (0.15)** †0.47 (0.17)** †0.47 (0.13)***
Costs 0.39 (0.19)** 0.28 (0.14). 0.06 (0.16) 0.17 (0.13)
Profitability 0 (0.16) 0.11 (0.14) 0.15 (0.15) 0.11 (0.15)
Cost-effectiveness 0.04 (0.19) 0.09 (0.16) 0.14 (0.19) 0.03 (0.17)
Individual level
Hedonic mot. †0.1 (0.05)** 0.01 (0.03) 0.01 (0.04) 0.02 (0.03)
Functional mot. 0.05 (0.07) 0.03 (0.05) 0.04 (0.05) 0.02 (0.04)
Social mot. †0.07 (0.04)** 0.05 (0.03) 0.01 (0.03) 0 (0.03)
Cognitive mot. 0.08 (0.05). 0.02 (0.04) 0.06 (0.06) 0.03 (0.03)
Experience 0.03 (0.02) 0.01 (0.01) 0.03 (0.02) 0.01 (0.02)
Scientific conf. 0.01 (0.02) 0.01 (0.01) 0.01 (0.01) 0 (0.01)
Sales visits 0.01 (0.01) 0 (0.01) 0.02 (0.01) 0 (0.01)
Senior phy. 0.5 (0.32) 0.55 (0.23)** 0.05 (0.29) 0 (0.35)
Attending phy. †1.48 (0.42)*** 0.21 (0.29) 0.78 (0.41). 0.63 (0.4)
Phy. †1.58 (0.64)** 0.42 (0.44) †1.35 (0.5)** †1.12 (0.48)**
Elec. 0.82 (0.33)** 0.19 (0.42) 0.59 (0.5) 0.09 (0.37)
Heart surgeon 1.49 (0.84) 0.86 (0.73) 0.68 (0.55) 0.33 (0.55)
Elec. and Int. car. 0.04 (0.54) 0.03 (0.46) 0.4 (0.38) 0.2 (0.58)
General cardio. 0.39 (0.48) 0.77 (0.41). 0.49 (0.35) 0.17 (0.43)
Other physician 0.98 (0.57) 0.22 (0.56) †1.06 (0.44)** 0.06 (0.57)
Sex (male) 0.27 (0.31) 0.27 (0.29) 0.15 (0.26) 0.01 (0.23)
Additional qual. 0.23 (0.39) 0.02 (0.27) 0.36 (0.39) 0.27 (0.49)
Organizational level
Hosp. size2 0.2 (0.39) 0.52 (0.34) 0.57 (0.39) 0.43 (0.26).
Hosp. size3 0.6 (0.49) 0.52 (0.4) 0.84 (0.44). 0.7 (0.34)**
Hosp. size4 †1.51 (0.41)*** 0.57 (0.4) †1.34 (0.36)*** 0.66 (0.39).
Hosp. size5 1.52 (0.82). 1.1 (0.72) 1.54 (0.88). 1.32 (0.9)
Department size 0.03 (0.16) 0.13 (0.13) 0.18 (0.16) 0.06 (0.12)
Budget pres. 0.12 (0.15) 0.15 (0.14) 0.1 (0.1) 0.18 (0.09)**
Competitive pres. 0.2 (0.14) 0.3 (0.12)** 0.15 (0.16) 0.04 (0.09)
Exp. ch. hum. res. 0.12 (0.19) †0.38 (0.17)** 0.06 (0.16) 0.26 (0.18)
Exp. ch. work flows 0.27 (0.22) 0.04 (0.16) 0.37 (0.15)** 0.27 (0.13)**
Exp. ch. plan. 0.09 (0.22) 0.25 (0.18) 0.11 (0.19) 0.1 (0.14)
Exp. ch. org. 0.13 (0.23) 0.06 (0.19) 0.31 (0.2) 0.13 (0.14)
Environmental level
Suburban region 0.17 (0.53) 1.05 (0.5)** 0.06 (0.55) 0.96 (0.47)**
Urban region 0.57 (0.4) 0.79 (0.39)** 0.44 (0.58) 0.82 (0.41)**
GDP 0 (0.01) 0 (0) †0.01 (0)*** 0 (0)
Out-of-pocket pay. 0.07 (0.28) 0.11 (0.19) †0.64 (0.14)*** 0.13 (0.21)
ICC 0.33 0.15 0.14 0.21
Significance: ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1. Values displayed are parameter estimates with standard errors in parentheses. A positive
value indicates a positive relationship of the variable with the likelihood of device adoption.
†These results were also significant (p-value <0.05) when using complete cases only to estimate the models
ICD: implantable cardioverter defibrillator; CRT: cardiac resynchronization therapy; DES: drug-eluting stent; TAVI: transcatheter aortic
valve implantation; RD: renal denervation; MC: MitraClip; LAA: left atrial appendage closure device; Man.: manufacturer; mot.: motiva-
tion; conf.: conference; Phy.: physician; Elec.: electrophysiologist; Int. car.: interventional cardiologist; qual.: qualification; Hosp.: hospital;
pres.: pressure; Exp.: expected; ch.: change; hum. res.: human resources; plan.: planning of activities; org.: organizational structure; pay.:
payment; ICC: intraclass correlation coefficient (the proportion of between country variance of the total variance).
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urban hospital location, and higher GDP were also associated with higher device utilization, while there
were fewer results for the role of medical evidence (only significant for LAA). The results for manufac-
turer support and GDP remained unchanged.
Table IV. Results of the random intercept hurdle models (truncated negative binomial part)
Devices
Covariates ICD CRT DES
Technology level
Intercept2 †2.36 (0.52)*** †1.63 (0.48)*** †4.77 (0.35)***
Medical evidence 0 (0.06) †0.12 (0.05)** 0.05 (0.04)
Man. support 0.01 (0.05) 0.12 (0.06)* 0.03 (0.04)
Costs 0.01 (0.04) 0.07 (0.04) 0.03 (0.03)
Profitability 0.04 (0.05) 0.02 (0.05) 0.02 (0.05)
Cost-effectiveness 0.03 (0.07) 0.06 (0.06) †0.11 (0.04)**
Organizational level
Hosp. size2 0.1 (0.14) 0.12 (0.11) 0.14 (0.11)
Hosp. size3 0.29 (0.15)* 0.06 (0.17) 0.09 (0.11)
Hosp. size4 †0.45 (0.19)* 0.2 (0.16) †0.36 (0.14)**
Hosp. size5 †0.69 (0.24)** 0.43 (0.23). 0.49 (0.25).
Department size †0.13 (0.05)** †0.14 (0.04)*** †0.12 (0.04)**
Environmental level
Suburban region 0.05 (0.19) 0.05 (0.27) 0.05 (0.12)
Urban region †0.62 (0.17)*** 0.47 (0.25). †0.31 (0.09)***
GDP 0.01 (0)* †0.01 (0)* 0 (0)
Out-of-pocket pay. 0.25 (0.13). †0.26 (0.1)** 0.13 (0.08).
ICC 0.45 0.42 0.41
Devices
Covariates TAVI RD MC LAA
Technology level
Intercept2 †2.69 (0.64)*** 1.03 (0.7) 1.75 (0.68)* 1.1 (0.72)
Medical evidence 0.05 (0.03) 0.07 (0.05) 0.09 (0.06) †0.18 (0.04)***
Man. support 0.09 (0.1) 0.06 (0.08) 0.28 (0.13)* †0.21 (0.1)*
Costs 0.02 (0.07) 0.06 (0.08) 0.02 (0.08) 0.05 (0.07)
Profitability 0.07 (0.05) 0.06 (0.06) 0.1 (0.11) †0.17 (0.07)*
Cost-effectiveness 0.06 (0.05) 0.03 (0.09) 0.06 (0.11) †0.21 (0.1)*
Organizational level
Hosp. size2 0.05 (0.25) 0.13 (0.2) 0.2 (0.25) 0.31 (0.2)
Hosp. size3 0 (0.28) 0.12 (0.27) 0.07 (0.25) 0.13 (0.25)
Hosp. size4 0.06 (0.29) 0.29 (0.29) 0.08 (0.22) 0.11 (0.16)
Hosp. size5 0.31 (0.36) 0.12 (0.43) †1 (0.4)* 0.13 (0.28)
Department size 0.02 (0.04) 0.1 (0.07) 0.02 (0.09) 0.13 (0.06)*
Environmental level
Suburban region 0.13 (0.2) 0.07 (0.46) 0.89 (0.5). 0.27 (0.55)
Urban region 0.3 (0.15)* 0.23 (0.36)† 0.9 (0.33)** 0.6 (0.5)
GDP †0.01 (0)*** 0 (0) 0 (0) 0 (0)
Out-of-pocket pay. †0.45 (0.13)*** 0.12 (0.15) 0.18 (0.18) 0.14 (0.1)
ICC 0.38 0.36 0.41 0.20
Significance:‘***’ 0.001‘**’ 0.01‘*’ 0.05 ‘.’ 0.1. Values displayed are parameter estimates and standard errors in parenthesis. A positive
value indicates a positive relationship of the variable with device utilization.
†These results were also significant (p-value <0.05) when using complete cases only to estimate the models.
ICD: implantable cardioverter defibrillator; CRT: cardiac resynchronization therapy; DES: drug-eluting stent; TAVI: transcatheter
aortic valve implantation; RD: renal denervation; MC: MitraClip; LAA: left atrial appendage closure device; Man.: manufacturer;
Hosp.: hospital; pay.: payment; ICC: intraclass correlation coefficient (the proportion of between country variance of the total
variance).
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4. DISCUSSION
This study represents a comprehensive analysis of factors driving the adoption and utilization of cardiovas-
cular medical devices. We investigated drivers at four different levels (i.e. environmental, organizational,
individual and technological) and identified patterns across devices, although the results of the random ef-
fects hurdle models were multifaceted. Our data were predominantly based on responses from chief and se-
nior physicians but also included responses from attending physicians and physicians (39%). Readers might
wonder how adoption decisions can be influenced by attending physicians and physicians. Although it is
probably true that chief and senior physicians have a higher formal impact on the adoption decision, lower
ranking physicians do influence adoption priority setting processes (Barasa et al., 2015; Wernz et al.,
2014). Therefore, we are convinced that the responses from attending physicians and physicians added sub-
stantial value to our adoption study and should not be disregarded.
The devices that were chosen for this study differed by stage in the diffusion process. The hurdle models
revealed that certain factors are associated with a higher adoption probability for some devices in our sam-
ple but not for others. This finding leads to the assumption that there are differences in the adoption and
utilization behaviours of physicians according to the length of time that the cardiovascular device has been
on the market. In the group of ‘new’ devices, better manufacturer support (as perceived by the physicians)
was associated with a higher probability of adoption. In the group of ‘old’ devices, there were no signifi-
cant findings for manufacturer support. With manufacturer support, physicians might be able to ‘test’ a new
device that seems promising for the treatment of patients (Harrington and Califf, 2010; DiPaola et al.,
2014). This implies that manufacturersˈ activities might even function as some kind of substitute for (strong
and unambiguous) medical evidence which is often not available for new devices (Clark and Linzer, 2014;
Maas and Hox, 2005).
We did not find that perceived medical evidence was a major driver of adoption. Its association with
adoption was only significant for ICD and TAVI (and this result was not stable in all of our sensitivity
analyses). However, this does not mean that medical evidence is irrelevant to cardiovascular device adop-
tion. Instead, our finding is largely a matter of our research question. In the survey, we asked adopters and
non-adopters to state the reasons for adopting or not adopting a specific device. We found that adopters
and non-adopters had similar perceptions of the devicesˈ medical evidence, respectively. If we had asked
the respondents to state the reasons for adopting one of the devices in our list instead of another, they
probably would have chosen one of the devices with better perceived medical evidence (e.g. ICD; CRT,
DES instead of RD, MC, LAA). This makes clear that our finding holds for comparisons of adopters
and non-adopters regarding a particular device but that it cannot be extended to settings in which different
devices are compared.
When examining the factors that influence the number of devices utilized, there were two significant find-
ings for medical evidence (CRT, LAA). In both cases, an increase in the perceived medical evidence supporting
these devices was associated with an increase in the number of devices adopted. Again, the assumption that
medical evidence is a major driver of adoption was only weakly supported.
Manufacturer support was associated with a lower number of CRTs, MCs and LAAs utilized. However, this
result was not confirmed for CRTs and MCs in the sensitivity analysis based on complete cases and should
therefore be treated with care.
Economic and financial aspects of the device (i.e. costs, profitability and cost-effectiveness) are often sug-
gested to be important drivers of device adoption and utilization (Bell et al., 2010; Barasa et al., 2015;
Greenberg et al., 2005; Mylotte et al., 2013); however, our findings do not support this assumption. So far, this
is consistent with the results of other empirical studies (Henschke et al., 2010; Greenhalgh et al., 2004). The
only significant estimate for costs in the context of initial adoption (logit models) was found for TAVI, and
it disappeared in our sensitivity analysis. Cost-effectiveness was significant for DES and LAA for device uti-
lization, but the parameter estimates had opposite signs. A reason for these results might be that physicians
are uncertain about financial figures. This was indicated by the high percentage of missing values (based on
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the percentage of ‘donˈt know’ answers) for the financial criteria (up to 26%). In contrast, the percentage of
missing values for medical evidence was much lower (the maximum was 7% missing values for the quality
of medical evidence for MC), which indicates that physicians are much more confident about their perceptions
of clinical information.
Other organizational- and environmental-level factors were found to be significant and associated
with adoption and utilization across several devices, including budget pressure for ICD, CRT, and
LAA. If budget pressure is influencing the adoption decision, the adoption probability of ICD and
CRT is higher. We interpret this result as a reflection of the economic reasoning of the physicians. Phy-
sicians who are under budget pressure might be more inclined to adopt established devices such as ICD
and CRT because they are less expensive and the corresponding reimbursement is predictable. Over
time, patent expiry and manufacturer competition lead to lower device prices and reimbursement sys-
tems have had time to fully incorporate device costs. In contrast, low budget pressure might foster
the adoption of new devices which are rather expensive and for which reimbursement might not yet
be fully established (we found a significant relationship for LAA in the base case model and the sub-
group analysis (p-value <0.5) but not in the sensitivity analysis based on complete cases). This is in
line with the assumption that budget pressure is related to the availability of ‘slack resources’ in a hos-
pital, which were found to be associated with a higher adoption probability of new, and therefore more
experimental, devices (Boriani et al., 2013; Cappellaro et al., 2011; Damanpour and Schneider, 2009;
Rye and Kimberly, 2007). However, readers should note we did not model a potential adoption
trade-off across devices. Instead, one has to interpret the effect of budget pressure on device adoption
on a single devices basis.
Variables such as greater hospital size and urban hospital location (compared to rural location) were
associated with an increased adoption probability (ICD, CRT, DES, TAVI, MC and ICD, CRT, DES,
RD, LAA). In terms of device utilization, these variables, as well as relatively larger cardiology depart-
ments, higher GDP and lower out-of-pocket payments, were related to higher device utilization, espe-
cially in the group of ‘old’ devices. Although the sensitivity analysis based on complete cases slightly
weakened these findings, they generally confirm what is known from the literature. That is, relatively
larger departments in larger hospitals that are located in more urban regions, which are often academic
teaching institutions or university hospitals, are more likely to adopt and utilize a higher numbers of de-
vices (Greenhalgh et al., 2004; Ghodeswar and Vaidyanathan, 2007; Nystrom et al., 2002; Wisdom
et al., 2014).
The organizational impact of adoption (i.e. expected changes in human resources, work-flows, planning
activities, and organizational structures) did not appear to be relevant to the adoption of devices. For TAVI,
it has been argued that organizational impact is of paramount importance to the diffusion of the technology
and cannot be neglected (Sorenson et al., 2011). However, our results reveal that clinicians either do not
consider or are unaware of this challenge. Another reason might be that the organizational impact of adop-
tion was measured on organizational and not on device level. This decision was based on considerations re-
lated to the feasibility of the survey (i.e. we incorporated four questions instead of 28) and on the assumption
that the organizational impact of implantable and catheter based cardiovascular devices (i.e. DES, TAVI,
RD, MC, LAA) is comparable.
Physiciansˈ motivation to adopt was not found to be a relevant factor of cardiovascular device adoption. A
reason could be that physiciansˈ personal motivation is superimposed by the interests of hospital managers. If
hospital managers exert their influence on adoption decisions, physicians might have to make compromises
which might decrease the relevance of physiciansˈ motivation to adopt. However, we believe that this depends
on the decision-making processes in hospitals and that a closer look at this topic is necessary to fully understand
the role of physiciansˈ motivation to adopt medical devices.
Some readers might wonder about the implicit similarities of our study design and established social cog-
nitive theories such as the theory of reasoned action (TRA) (Fishbein and Ajzen, 1975), the theory of
planned behaviour (TPB) (Ajzen, 1985), the Technology Acceptance Model (TAM) (Davis, 1986; Venkatesh
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and Davis, 2000; Venkatesh and Bala, 2008), and the unified theory of acceptance and use of technology
(UTAUT) (Venkatesh et al., 2003). All of these theories were developed to explain behaviour, behavioural
intention to use, or use behaviour on individual level. Although a relationship between the variables included
in our study and the mentioned theories can be found, we did not base our study on one of these theories
because they were not designed to capture the specific characteristics of the health care context. For exam-
ple, TAM and UTAUT were developed in a consumer context to explain information technology acceptance,
the theories include individual level variables only, and they do not consider the important characteristics of
physiciansˈ adoption situations (e.g. the trade-off between physiciansˈ and patientsˈ interests, the divergence
between adopter and end user, the possibility of group decision making in hospitals, the strong impact of
health care system conditions on adoption decisions such as market access restrictions and reimbursement
etc.). Therefore, we decided against building our study upon the mentioned theoretical frameworks. How-
ever, we are convinced that a new or adapted theoretical framework would add value to adoption research
in health care.
Taken together, the results of this study contribute to the literature regarding several important as-
pects. To the best of our knowledge, this study is based on one of the largest surveys available
(Ghodeswar and Vaidyanathan, 2007), covering up to 89 countries and seven cardiovascular devices.
Answering the call for broad analyses (Bech et al., 2009; Arribas et al., 2014; Fleuren et al., 2004;
Berta et al., 2005), our study considered factors at four different levels. This includes factors at the
innovation level, which have rarely been studied (Robert et al., 2010). Furthermore, gaps in the liter-
ature, such as the role of manufacturer activities (included as the manufacturer support variable) and
the role of physician motivation in the adoption of medical devices, have been addressed by our paper.
Overall, our results were multifaceted, but they offered new insights into the roles of some major var-
iables (i.e. medical evidence, financial aspects, manufacturer support) while confirming findings from
other studies (e.g. the relevance of organization size, hospital location and GDP for the adoption of
medical devices).
This study is also subject to limitations. First, our response rate was rather low if one includes the
number of people who clicked on the ESC newsletter in the denominator (3%). However, the response
rate was much higher if considering the number of clicks on the link to the survey in the denominator
(36%). We recommend using the latter number because physicians who have not noticed the link to
our survey in the ESC newsletter do not represent potential participants. Nevertheless, a low response rate
might be a source of non-response bias. Therefore, we conducted visual inspection to compare our data to
the ESC data. We compared the numbers of observations from the different countries in our data set to
the numbers of members in the ESC member and affiliate societies as published on the ESC website. Al-
though our data set contained more responses from some ESC member societies (e.g. Italy, Spain) and
fewer responses from ESC affiliate societies (e.g. Japan, Brazil, Chile, Argentina), the overall differences
between both data sets were small which lowers the probability of a substantial non-response bias. A pos-
sible explanation for the differences might be found in existing language barriers especially in the ESC
affiliate societies. Second, our data structure did not allow for the estimation of fixed effects models using
the original data set; only a fraction of the overall observations were used. This complicated the compar-
ison with our base case random effects model. However, estimating the fixed effects models was still use-
ful in the sensitivity analysis because the comparison of these fixed effects models and random effects
models based on the reduced data sets revealed that both types of model yield similar results. Therefore,
a general advantage of fixed effects models, that unobserved sources of variation are allowed to correlate
with the explanatory variables in the model (Lansisalmi et al., 2006), did not seem to be overly impor-
tant. Third, the percentage of missing values (the proportion of ‘donˈt know’ answers) was rather high for
some device-related factors, especially for the financial variables for RD, MC, and LAA. This indicates
that physicians are uncertain of these figures. Although we corrected for this bias using multiple imputa-
tion, we did not find a clear pattern concerning the influence of financial variables on the adoption or
utilization of cardiovascular devices. However, it is possible that these findings change when a target
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population with more certainty about financial aspects (e.g. hospital managers) is used to study adoption.
Therefore, future studies should discuss this topic in the context of our results. Fourth, the scale used to
measure physiciansˈ motivations for adoption was originally developed in a consumer context. We incor-
porated the scale developed by Vandecasteele and Geuens (2010) because, to the best of our knowledge,
no specific scale has been developed and validated in a medical context to measure physician motivation.
Although results of the factor analyses were satisfying, we recommend that future researchers use more
specific and validated scales for measuring physiciansˈ motivation, if these are available.
5. CONCLUSIONS AND IMPLICATIONS FOR HTA OF MEDICAL DEVICES
In this study, we used a broad approach to analyse the effects of selected factors on the adoption and utilization
of cardiovascular devices.
Our findings have several implications for HTA of medical devices. We found evidence that the role of
external stakeholders (i.e. through manufacturer support) is highly important and should be further investi-
gated. Manufacturer support was identified as a major driver of physiciansˈ decisions to adopt new devices.
We assume that manufacturers conduct activities targeting certain physicians or hospitals (Brennan et al.,
2006) that are the starting point for subsequent diffusion processes. Furthermore, manufacturers probably
target the hospitals that are of greater size and located in urban areas. We recommend investigating the
types and forms of such activities in more detail and across different kinds of medical devices to help
decision makers to get a better understanding of the diffusion patterns of newly introduced medical devices
and about the relationship between manufacturer support and key individuals or hospitals in the diffusion
process.
The role of manufacturer support is also relevant for the health economic evaluation of medical devices. As-
suming that manufacturer support is provided in the form of hands-on tests, educational, and learning activities
(Harrington and Califf, 2010; DiPaola et al., 2014; Steinman et al., 2012), it functions as a substitute for med-
ical evidence and reduces uncertainty. This refers especially to medical devices that were recently introduced to
the market because sufficient medical evidence, that is, data on efficacy and effectiveness, are often not avail-
able for such devices (Avorn and Choudhry, 2010; Schreyogg et al., 2009). Thus, manufacturer support may
impact the effectiveness of a medical device through learning and therefore also has an effect on cost-
effectiveness analyses. Quantifying these effects could provide new insights into the relationship of manufac-
turer support with learning effects and cost-effectiveness.
Although our findings supporting the relevance of medical evidence are scarce, its role should not be
disregarded. Our descriptive results demonstrate that physicians differentiate between the quality and quan-
tity of medical evidence of the different cardiovascular devices. However, we also found that adopters and
non-adopters do not have different perceptions of the medical evidence regarding a particular device (i.e.
both groups assess a deviceˈs medical evidence to be equal). A reason might be that published results
are likewise available to adopters and non-adopters (although this does not seem to hold for information
in the form of manufacturer support). If adopters and non-adopters have similar perceptions of this evi-
dence, then it cannot be a relevant factor for the adoption decision of a particular device on individual
or organizational level. Instead, it might rather function as a ‘threshold’ factor and a factor influencing
the adoption rate in the system. We suppose that a similar mechanism explains the results for the financial
criteria. Decision makers could use this information to prioritize other variables (e.g. manufacturer support)
if they want to know why some physicians or hospitals adopt medical devices and others do not and to
identify diffusion patterns. However, to forecast the adoption rate and extent of diffusion throughout the
system of a particular device, medical evidence and financial criteria (and especially their changes over
time) will need to be considered.
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